Nicotine dependence and smoking cessation
Tobacco use is the single most preventable cause of death, disability and disease in the world and is projected to be the leading cause of death and disability across all developed and developing countries by 2020. Nicotine, the primary active ingredient of cigarettes that contributes to physical dependence, acts on nicotine receptors in the central nervous system and leads to the release of neurotransmitters (such as dopamine). Like other drugs of abuse, nicotine is thought to produce reinforcing effect by activating the mesocorticolimbic dopamine system. A wide variety of cessation treatments of nicotine dependence is commercially available, yet only 2 general approaches have received empirical validation: behavioral intervention (including 5 As brief intervention) and pharmacotherapy. The evidences show that 5 As brief intervention is one of the most cost-effective treatments in clinical work for busy physicians. Three types of medications have been available in market for smoking cessation treatment: nicotine replacement treatment (NRT, i.e., transdermal patch, gum, inhaler, nasal spray, and lozenge), sustained release bupropion and varenicline. Varenicline, a novel alpha4beta2 nicotinic receptor partial agonist, is effective for tobacco dependence. Phase III trials suggest that it is more effective than NRT and bupropion SR. The safety profile of varenicline is excellent, with the most commonly occurring adverse events, nausea, typically mild and well tolerated. However, new safety warnings are added to the varenicline label because of post-marketing report including agitation, depression and suicidality. A causal connection between varenicline use and these symptoms has not been established.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences - 34(2009), 11 vom: 01. Nov., Seite 1049-57 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tan, Linxiang [VerfasserIn] |
|---|
| Themen: |
01ZG3TPX31 |
|---|
| Anmerkungen: |
Date Completed 02.05.2011 Date Revised 19.11.2015 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM193191784 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM193191784 | ||
| 003 | DE-627 | ||
| 005 | 20231223194317.0 | ||
| 007 | tu | ||
| 008 | 231223s2009 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0644.xml |
| 035 | |a (DE-627)NLM193191784 | ||
| 035 | |a (NLM)19952392 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tan, Linxiang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nicotine dependence and smoking cessation |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2011 | ||
| 500 | |a Date Revised 19.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tobacco use is the single most preventable cause of death, disability and disease in the world and is projected to be the leading cause of death and disability across all developed and developing countries by 2020. Nicotine, the primary active ingredient of cigarettes that contributes to physical dependence, acts on nicotine receptors in the central nervous system and leads to the release of neurotransmitters (such as dopamine). Like other drugs of abuse, nicotine is thought to produce reinforcing effect by activating the mesocorticolimbic dopamine system. A wide variety of cessation treatments of nicotine dependence is commercially available, yet only 2 general approaches have received empirical validation: behavioral intervention (including 5 As brief intervention) and pharmacotherapy. The evidences show that 5 As brief intervention is one of the most cost-effective treatments in clinical work for busy physicians. Three types of medications have been available in market for smoking cessation treatment: nicotine replacement treatment (NRT, i.e., transdermal patch, gum, inhaler, nasal spray, and lozenge), sustained release bupropion and varenicline. Varenicline, a novel alpha4beta2 nicotinic receptor partial agonist, is effective for tobacco dependence. Phase III trials suggest that it is more effective than NRT and bupropion SR. The safety profile of varenicline is excellent, with the most commonly occurring adverse events, nausea, typically mild and well tolerated. However, new safety warnings are added to the varenicline label because of post-marketing report including agitation, depression and suicidality. A causal connection between varenicline use and these symptoms has not been established | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Benzazepines |2 NLM | |
| 650 | 7 | |a Dopamine Uptake Inhibitors |2 NLM | |
| 650 | 7 | |a Nicotinic Agonists |2 NLM | |
| 650 | 7 | |a Quinoxalines |2 NLM | |
| 650 | 7 | |a Bupropion |2 NLM | |
| 650 | 7 | |a 01ZG3TPX31 |2 NLM | |
| 650 | 7 | |a Varenicline |2 NLM | |
| 650 | 7 | |a W6HS99O8ZO |2 NLM | |
| 700 | 1 | |a Tang, Quansheng |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences |d 2004 |g 34(2009), 11 vom: 01. Nov., Seite 1049-57 |w (DE-627)NLM155183753 |x 1672-7347 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2009 |g number:11 |g day:01 |g month:11 |g pages:1049-57 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2009 |e 11 |b 01 |c 11 |h 1049-57 | ||